FGF23 and X-linked hypophosphatemia: XLH treatments include oral phosphate and active vitamin D—which are associated with a burdensome dosing regimen, gastrointestinal disturbances, hyperparathyroidism, and nephrocalcinosis—or burosumab, a fully human anti-FGF23 antibody.